Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Graphene Nanocomposites in the Targeting Tumor Microenvironment: Recent Advances in TME Reprogramming

A. Kolokithas-Ntoukas, A. Mouikis, A. Angelopoulou

. 2025 ; 26 (10) : . [pub] 20250509

Language English Country Switzerland

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc25015762

Graphene-based materials (GBMs) have shown significant promise in cancer therapy due to their unique physicochemical properties, biocompatibility, and ease of functionalization. Their ability to target solid tumors, penetrate the tumor microenvironment (TME), and act as efficient drug delivery platforms highlights their potential in nanomedicine. However, the complex and dynamic nature of the TME, characterized by metabolic heterogeneity, immune suppression, and drug resistance, poses significant challenges to effective cancer treatment. GBMs offer innovative solutions by enhancing tumor targeting, facilitating deep tissue penetration, and modulating metabolic pathways that contribute to tumor progression and immune evasion. Their functionalization with targeting ligands and biocompatible polymers improves their biosafety and specificity, while their ability to modulate immune cell interactions within the TME presents new opportunities for immunotherapy. Given the role of metabolic reprogramming in tumor survival and resistance, GBMs could be further exploited in metabolism-targeted therapies by disrupting glycolysis, mitochondrial respiration, and lipid metabolism to counteract the immunosuppressive effects of the TME. This review focuses on discussing research studies that design GBM nanocomposites with enhanced biodegradability, minimized toxicity, and improved efficacy in delivering therapeutic agents with the intention to reprogram the TME for effective anticancer therapy. Additionally, exploring the potential of GBM nanocomposites in combination with immunotherapies and metabolism-targeted treatments could lead to more effective and personalized cancer therapies. By addressing these challenges, GBMs could play a pivotal role in overcoming current limitations in cancer treatment and advancing precision oncology.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015762
003      
CZ-PrNML
005      
20250731091220.0
007      
ta
008      
250708s2025 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms26104525 $2 doi
035    __
$a (PubMed)40429669
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kolokithas-Ntoukas, Argiris $u Department of Pharmacy, School of Health Sciences, University of Patras, GR-26504 Patras, Greece $u Regional Centre of Advanced Technologies and Materials, Czech Advanced Technology and Research Institute (CATRIN), Palacky University Olomouc, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000185920380
245    10
$a Graphene Nanocomposites in the Targeting Tumor Microenvironment: Recent Advances in TME Reprogramming / $c A. Kolokithas-Ntoukas, A. Mouikis, A. Angelopoulou
520    9_
$a Graphene-based materials (GBMs) have shown significant promise in cancer therapy due to their unique physicochemical properties, biocompatibility, and ease of functionalization. Their ability to target solid tumors, penetrate the tumor microenvironment (TME), and act as efficient drug delivery platforms highlights their potential in nanomedicine. However, the complex and dynamic nature of the TME, characterized by metabolic heterogeneity, immune suppression, and drug resistance, poses significant challenges to effective cancer treatment. GBMs offer innovative solutions by enhancing tumor targeting, facilitating deep tissue penetration, and modulating metabolic pathways that contribute to tumor progression and immune evasion. Their functionalization with targeting ligands and biocompatible polymers improves their biosafety and specificity, while their ability to modulate immune cell interactions within the TME presents new opportunities for immunotherapy. Given the role of metabolic reprogramming in tumor survival and resistance, GBMs could be further exploited in metabolism-targeted therapies by disrupting glycolysis, mitochondrial respiration, and lipid metabolism to counteract the immunosuppressive effects of the TME. This review focuses on discussing research studies that design GBM nanocomposites with enhanced biodegradability, minimized toxicity, and improved efficacy in delivering therapeutic agents with the intention to reprogram the TME for effective anticancer therapy. Additionally, exploring the potential of GBM nanocomposites in combination with immunotherapies and metabolism-targeted treatments could lead to more effective and personalized cancer therapies. By addressing these challenges, GBMs could play a pivotal role in overcoming current limitations in cancer treatment and advancing precision oncology.
650    _2
$a lidé $7 D006801
650    12
$a nádorové mikroprostředí $x účinky léků $7 D059016
650    12
$a grafit $x chemie $x terapeutické užití $7 D006108
650    12
$a nanokompozity $x chemie $x terapeutické užití $7 D053761
650    _2
$a zvířata $7 D000818
650    12
$a nádory $x farmakoterapie $x metabolismus $7 D009369
650    _2
$a lékové transportní systémy $x metody $7 D016503
650    _2
$a imunoterapie $x metody $7 D007167
650    _2
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Mouikis, Andreas $u Department of Pharmacy, School of Health Sciences, University of Patras, GR-26504 Patras, Greece $1 https://orcid.org/0009000468750876
700    1_
$a Angelopoulou, Athina $u Department of Pharmacy, School of Health Sciences, University of Patras, GR-26504 Patras, Greece $u Metabolic Engineering and Systems Biology Laboratory, Institute of Chemical Engineering Sciences, Foundation for Research and Technology-Hellas (FORTH/ICE-HT), GR-26504 Patras, Greece $1 https://orcid.org/0000000172771590
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 26, č. 10 (2025)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40429669 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091215 $b ABA008
999    __
$a ok $b bmc $g 2366540 $s 1252887
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 26 $c 10 $e 20250509 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20250708
Back

Find record

Citation metrics

Archiving options